Anti-VEGFs worth the cost the government pays, SFO president says

PARIS — The current price of anti-VEGFs is not too high, considering the benefits they provide, according to Jean-François Korobelnik, MD, president of the French Society of Ophthalmology. “The media have put a lot of emphasis on the cost of anti-VEGFs. But we are investing on expensive treatments also for cancer to prolong life of a few months, and new promising molecules for hepatitis C are going to cost €60,000 for 3 months of therapy,” he said.